Lee's Pharmaceutical Holdings Limited

SEHK:950 Stock Report

Market Cap: HK$712.5m

Lee's Pharmaceutical Holdings Balance Sheet Health

Financial Health criteria checks 5/6

Lee's Pharmaceutical Holdings has a total shareholder equity of HK$1.6B and total debt of HK$231.5M, which brings its debt-to-equity ratio to 14.2%. Its total assets and total liabilities are HK$2.5B and HK$921.4M respectively. Lee's Pharmaceutical Holdings's EBIT is HK$70.7M making its interest coverage ratio 6.5. It has cash and short-term investments of HK$195.0M.

Key information

14.2%

Debt to equity ratio

HK$231.47m

Debt

Interest coverage ratio6.5x
CashHK$194.99m
EquityHK$1.63b
Total liabilitiesHK$921.43m
Total assetsHK$2.55b

Recent financial health updates

Recent updates

Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem

Sep 04
Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem

There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price

Aug 07
There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price

Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

May 21
Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Dec 20
Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

May 21
Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Apr 02
Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Aug 29
Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Does Lee's Pharmaceutical Holdings (HKG:950) Have A Healthy Balance Sheet?

Apr 05
Does Lee's Pharmaceutical Holdings (HKG:950) Have A Healthy Balance Sheet?

Can Mixed Fundamentals Have A Negative Impact on Lee's Pharmaceutical Holdings Limited (HKG:950) Current Share Price Momentum?

Mar 17
Can Mixed Fundamentals Have A Negative Impact on Lee's Pharmaceutical Holdings Limited (HKG:950) Current Share Price Momentum?

Should You Buy Lee's Pharmaceutical Holdings Limited (HKG:950) For Its 0.9% Dividend?

Feb 22
Should You Buy Lee's Pharmaceutical Holdings Limited (HKG:950) For Its 0.9% Dividend?

What Type Of Returns Would Lee's Pharmaceutical Holdings'(HKG:950) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Jan 29
What Type Of Returns Would Lee's Pharmaceutical Holdings'(HKG:950) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Financial Position Analysis

Short Term Liabilities: 950's short term assets (HK$696.8M) exceed its short term liabilities (HK$632.6M).

Long Term Liabilities: 950's short term assets (HK$696.8M) exceed its long term liabilities (HK$288.8M).


Debt to Equity History and Analysis

Debt Level: 950's net debt to equity ratio (2.2%) is considered satisfactory.

Reducing Debt: 950's debt to equity ratio has increased from 5.4% to 14.2% over the past 5 years.

Debt Coverage: 950's debt is well covered by operating cash flow (56.2%).

Interest Coverage: 950's interest payments on its debt are well covered by EBIT (6.5x coverage).


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 11:54
End of Day Share Price 2025/02/07 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lee's Pharmaceutical Holdings Limited is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Cheng3V Capital Limited
Yue-Kwong LuiBOCOM International Securities Limited
Chu WangCitigroup Inc